---
title: "CCHT submits H-share listing application"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/259286457.md"
description: "CCHT today submitted an H-share listing application to the Stock Exchange, planning to list on the main board. The funds raised from this issuance will be used for clinical trials, project development, market expansion, and operating capital. The company's revenue for the first half of the year was 6.603 billion yuan, with a net profit of 980 million yuan, representing year-on-year declines of 0.5% and 42.8%, respectively. CCHT has full industry chain capabilities in therapeutic biologics, chemical drugs, and other fields, with sales revenue reaching 12.7 billion yuan last year"
datetime: "2025-09-29T08:36:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259286457.md)
  - [en](https://longbridge.com/en/news/259286457.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259286457.md)
generator: "portal-rs"
---

# CCHT submits H-share listing application

China's leading innovation-driven pharmaceutical group CCHT (000661.SZ) announced today (29th) that it has submitted an application to the Hong Kong Stock Exchange for the issuance of overseas listed foreign shares (H shares) and for listing on the main board of the Hong Kong Stock Exchange. The relevant application materials for this issuance and listing have been prepared and published by the company in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange, and are in draft form. The information contained may be updated and revised in due course, and investors should not make any investment decisions based on this information.

According to the preliminary prospectus, CCHT's exclusive sponsor is CITIC Securities International. The net proceeds from the listing are intended to be used for clinical trials of innovative pipelines, advancing the development of preclinical projects and related regulatory affairs; potential global collaborations and co-development; expanding clinical and commercialization teams in overseas markets; enhancing sales and marketing capabilities; working capital and other general corporate purposes.

The company's revenue for the first half of this year reached RMB 6.603 billion, a year-on-year decrease of 0.5%, with net profit falling 42.8% to RMB 980 million.

CCHT's business covers therapeutic biological agents, chemical drugs, vaccines, and traditional Chinese medicine, encompassing all major drug registration types in China.

According to Frost & Sullivan, CCHT is one of the few pharmaceutical companies in the country that has achieved full industry chain capabilities in research and development, production, and commercialization for the above drug types. The company's pharmaceutical product sales revenue reached RMB 12.7 billion last year, achieving over RMB 10 billion for four consecutive years. Since 2017, the company has been listed among the "Top 100 Pharmaceutical Enterprises in China" for eight consecutive years

### Related Stocks

- [000661.CN](https://longbridge.com/en/quote/000661.CN.md)

## Related News & Research

- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [SandboxAQ introduces AQPotency for virtual drug screening](https://longbridge.com/en/news/296467103.md)
- [Rapala VMC: Strong H1 sales and profit growth led to upgraded full-year outlook amid ongoing trade risks](https://longbridge.com/en/news/296480810.md)
- [DIMRI: H1 2026 net profit rose to ₪495.6M on revenue of ₪780.5M, with robust liquidity and equity](https://longbridge.com/en/news/296448412.md)
- [Shurgard announces availability of FY2025 full-year results report](https://longbridge.com/en/news/296451547.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**